Tierney David S's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 28, 2025
- Accession no.
- 0001161697-25-000302
- Filed
- Aug 28, 2025
- Trade date
- Aug 27, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $525.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tierney David SCIK 0001292636 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2025 | Common Stock, par value $0.001 per share | MOption exerciseAcquired | +50,000 | $2.24 | +$112,000 | 405,620 | Direct | |
| Aug 27, 2025 | Common Stock, par value $0.001 per share | SSaleDisposed | −26,000 | $20.20F1,F2 | −$525,200 | 379,620 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2025 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 158,274 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold on the open market to fund the exercise price and estimated taxes due from Reporting Person as a result of the exercise of the stock options reported on Table II.
Referenced by the price of 1 transaction in Table I.
- F2
Represents a weighted average sales price for the shares sold. Shares were sold in a range from $20.10 to $20.32 per share.
Referenced by the price of 1 transaction in Table I.